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CASE STUDY
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Abstract 
Background: Nimesulide is a non-steroidal anti-inflammatory drug with antipyretic and analgesic properties, which 
is still used in many countries despite its known hepatotoxicity. Along with hepatotoxicity it has also been associated 
with several other Adverse Drug Reactions (ADRs) including leukocytoclastic vasculitis (LCV).
Case description: A 38 year-old female presented with history of acute onset fever for which she took tablet nime-
sulide and paracetamol combination (100 mg Nimesulide + 500 mg paracetamol tablet), 1 tab three times daily for 
4 days, following which she developed rash all over the body. She also had clinical and biochemical evidence of acute 
hepatitis. Histopathological examination of the skin rash documented the presence of LCV. She was managed symp-
tomatically with anti-inflammatory and supportive therapy and was not further exposed to nimesulide.
Discussion and evaluation: Our case demonstrates occurrence of acute hepatitis and LCV associated with nime-
sulide intake. The case meets the defining criteria for the diagnosis of LCV preceded by history of nimesulide intake. 
There was also clinical and biochemical evidence of hepato-cellular damage which supports the concurrent develop-
ment of hepatitis along with the development of LCV following nimesulide use. To the best of our knowledge there 
is no previous published report of LCV and hepatitis occurring concurrently in the same patient following nimesulide 
intake. Nimesulide should be added to the list of agents associated with these serious adverse drug reactions.
Conclusions: Nimesulide has been a contentious drug over many years. Under such evidence of serious ADRs the 
scientific community should consider ensuring strict pharmacovigilance with respect to its use especially in the 
developing countries where such monitoring systems are inadequate.
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Background
Nimesulide is a non-steroidal anti-inflammatory drug 
(NSAID) with antipyretic and analgesic properties. It is 
a selective cyclooxgenase-2 inhibitor and has been used 
in the treatment of a variety of inflammatory condition 
for last three decades in many countries of the world. 
Although it has been claimed to have a lower incidence 
of adverse gastro-intestinal effects, this has never been 
clearly demonstrated. On the contrary, numerous reports 
of Adverse Drug Reactions (ADR) have been attributable 
to nimesulide in the literature (WHO ADR Newslet-
ter 1999). Some of the reported adverse effects include 
peripheral oedema, gastritis, stomatitis, necrotising fas-
ciitis, Reye’s syndrome and coagulopathy with elevated 
liver enzymes and acute hepatitis.
Hypersensitivity vasculitis (HSV), which is usually rep-
resented histopathologically by leukocytoclastic vascu-
litis (LCV), is a term commonly used to denote a small 
vessel vasculitis (Lie 1994). Approximately 50% of cases 
of LCV are idiopathic with drugs, malignancies and con-
nective tissue disorders accounting for a majority of the 
remaining cases (Tai et  al. 2006). In a study from India 
it has been shown that drugs were the most common 
etiological factor associated with hypersensitivity vascu-
litis (HSV) of which the most commonly implicated were 
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NSAIDs (Khetan et al. 2012). Few reports of nimesulide 
induced vasculitis have also been described in the litera-
ture (Polimeni et al. 2006).
Nimesulide has been a drug which has been subjected 
to controversies in the past. However, in spite of reports 
of serious ADR its usage continues to be in vogue in med-
ical practice in many developing countries. Though the 
association of cutaneous reactions and of hepatitis with 
nimesulide use has been described separately, to the best 
of our knowledge, there is no report in the literature of 
the concurrent development of both hepatitis and vascu-
litis with the use of this molecule. With this background 
we report from India a case of hepatitis and LCV associ-
ated with the use of nimesulide.
Case description
A 38 year old female presented with history of acute onset 
fever with body ache for which she took tablet nime-
sulide and paracetamol combination (100  mg Nime-
sulide + 500 mg paracetamol tablet), 1 tab three times daily 
for 4 days, following which she developed rash all over the 
body. She also complained of itching all over her body and 
of high colour urine. There was no history of oral or geni-
tal ulcerations, photosensitivity or joint pain. There was no 
history of allergy to drug including paracetamol. There was 
no history of intake of herbal or dietary supplements.
On examination the patient was afebrile with a 
pulse rate of 76 beats per minute, blood pressure of 
110/70 mmHg and respiratory rate of 16/minute. She had 
mild icterus, few small (<1  cm) non tender, right upper 
cervical lymph nodes and a soft and tenderly enlarged 
liver. Rashes were present over the trunk and all four 
extremities along with a malar rash over her face (Fig-
ure 1). Initially the rash was erythematous in the form of a 
palpable purpura and the lesions were small and punctate, 
but later on the lesions increased in size and coalesced to 
form extensive large blackish deep purple patches in both 
upper limbs (Figure  2). There were small digital infarcts 
of her toes bilaterally (Figures 3, 4). Other systems yielded 
no clinical abnormalities. Blood biochemistry (Table  1) 
revealed deranged liver function suggestive of cholestatic 
jaundice with mildly altered coagulation profile. Except 
for a mild anaemia the haematological profile was nor-
mal. Other biochemical parameters (blood glucose, serum 
electrolytes and renal functions) were normal. The anti 
nuclear antibody (ANA) and Rheumatoid Factor were 
negative. The viral markers for HIV-AIDS and hepatitis B 
& C were non reactive. Blood culture (three samples taken 
within 12  h of hospitalization), as well as urine culture 
were sterile. Except for hepatomegaly, the ultra-sonogra-
phy of abdomen was normal. Arterial and venous Dop-
pler studies of the extremities as well as CT angiography 
of upper limbs were also normal. Biopsy from the skin 
lesions of the upper limb showed features of LCV (Fig-
ures 5, 6, 7, 8, 9).
Considering the history of nimesulide intake preceding 
the development of hepatitis and LCV in the absence of 
Figure 1 Showing the malar rash in the patient with leukocytoclastic 
vasculitis an hepatitis.
Figure 2 Showing the lesions in the upper limbs which have coa-
lesced into large blackish deep purple patches.
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any evidence of an infective or autoimmune etiology and 
normal Doppler and CT-angiography of the extremities, 
a diagnosis of nimesulide induced hepatitis and LCV has 
been made.
The patient was treated with systemic corticosteroids 
(methyl prednisolone in a dose of 1 gm/day intravenously 
for 3 days followed by oral prednisolone in tapering dose) 
and other supportive measures. Gradually there was 
improvement with disappearance of the skin lesions (Fig-
ure 10) and healing of the digital infarcts. Blood parameters 
also showed improvement with normalisation of liver func-
tion tests by the ninth day (Table 1). She was discharged on 
the tenth day and was doing well on follow up after 3 weeks.
Discussion and evaluation
In the present case report the patient had clinical and 
biochemical features of hepatitis which developed 
Figure 3 Showing the digital infarcts of the toes of both lower limbs.
Figure 4 Showing the digital infarcts of the toes of both lower limbs.
Table 1 Showing Laboratory findings in  the patient with 






On admission At discharge
Haemogram
 Haemoglobin  
(gm/dL)
10.5 10.9 12–18
 Total Leucocytic 
count (×103/mm3)
8.50 8.60 4.0–11.0
 Differential leucocytic count (%)
  Neutrophil 82 80 40–75
  Lymphocyte 16 18 20–45
  Monocyte 02 02 2–10
  Eosinophil 00 00 1–6
  Basophil 00 00 ≤1
 Platelet count (×103/
mm3)




02 Not done 0–20
Liver function tests
 Bilirubin (mg/dL)
  Total 6.0 1.9 0.3–1.3
  Direct 3.4 0.5 0.1–0.4
  Indirect 2.6 1.4 0.2–0.9
 ALT (U/L) 173 126 7–41
 AST (U/L) 295 42 12–38
 Alkaline phosphatase 
(IU/L)
467 236 30–120
 Protein, total (g/dL) 5.1 5.7 6.3–8.2
 Albumin (g/dL) 2.6 3.0 3.5–5.0
 Globulin (g/dL) 2.5 2.7 1.5–3.0
Coagulation profile
 Prothrombin  
time (s)
18.1 14.2 12.7–15.4
 INR 1.47 1.38 1.34
 APTT (s) 41.2 38.2 26.3–39.4
Renal profile
 Serum creatinine 
(mg/dL)
1.1 1.0 0.5–0.9
 Blood urea (mg/dL) 42 38 10–50
 Sodium (meq/L) 136 138 135–145
 Potassium (meq/L) 3.6 3.8 3.5–5.5
 Calcium (mg/dL) 9.2 9.3 8.7–10.2




Blood culture Sterile Not done
Urine culture Sterile Not done
Antinuclear antibody Negative Not done
Rheumatoid factor Negative Not done
HIV I, II Non Reactive Not done
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within 4–5  days of exposure to the drug. Liver biopsy 
was not performed. Drug induced hypersensitivity vas-
culitis can be identified on the basis of the following five 
characteristics (Calabrese et al. 1990): (1) age >16 years, 
(2) use of possible offending drug in temporal relation 
to the symptoms, (3) palpable purpura, (4) maculopapu-
lar rash and (5) biopsy of the skin showing neutrophils 
around an arteriole or venule. Our case also satisfies 
all the five criteria of LCV as evidenced clinically and 
histopathologically. Both the hepatitis and vasculitis of 
the patient gradually regressed and resolved following 
withdrawal of the offending drug and symptomatic 
treatment.
Nimesulide induced hepatotoxicity is a well known 
ADR. It has been shown to cause hepatic lesions more 
often in older women and the liver injury has been 
reported more commonly hepatocellular rather than 
cholestatic (Van Steenbergen et  al. 1998). In another 
study, acute liver injury developed in 3 of 726 patients 
treated with nimesulide (McCormick et  al. 1999). The 
exact molecular mechanism for hepatotoxicity has not 
been fully elucidated and in most instances it is thought 
to be an idiosyncratic reaction (Boelsterli 2002). Nime-
sulide induced hepatotoxicity has been shown to develop 
after about 15  days in two-thirds of patients (Bessone 
2010), accordingly EMEA has recommended a dose of 
100 mg per day (Bessone 2010). In our case, the patient 
had received 300  mg of nimesulide per day for 4  days, 
which could be the possible reason for the early devel-
opment of hepatotoxicity. Because of its known tox-
icities, many developed countries have not allowed the 
ALT alanine aminotransferase, AST aspartate aminotransferase, INR international 






On admission At discharge
HBsAg Negative Not done
Anti HCV Negative Not done
Figure 5 Histopathological examination of biopsy of the skin lesion from the upper arm showing leukocytoclastic reaction. a, b Hematoxylin and 
Eosin staining showing the epidermis lined by keratinizing stratified squamous epithelium with evidence of spongiosis. Most of the blood vessels in 
underlying dermis showing thrombus formation along with necrosis in the vascular wall and neutrophilic infiltration. c, d Periodic acid schiff stain-
ing of the same skin lesions showing amorphus PAS positive material deposits (red arrows) in form of intramural and intravascular thrombus.
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manufacturing and marketing of nimesulide. Further, in 
some other countries its production and marketing was 
withdrawn after several instances of severe hepato-toxic-
ity were reported following the use of nimesulide. In few 
cases this had even led to severe hepatic failure requir-
ing liver transplantation or fatality (Polimeni et al. 2006). 
Despite these known toxicities it is still being used in 
some developing countries.
Hypersensitivity vasculitis (HSV), which is usually rep-
resented histopathologically by LCV, is a term commonly 
used to denote a small vessel vasculitis (Lie 1994). LCV or 
HSV may be idiopathic, drug induced or can occur be a part 
of a known disorder like infection. Many drugs including 
NSAIDs have been implicated in the development of LCV 
(Martinez-Taboada et al. 1997; Ekenstam and Callen 1984).
Although a precise pathophysiologic mechanism has 
not yet been identified for the development of LCV, sev-
eral theories have been proposed. The involvement of T 
cells, which is evidenced by positive patch tests and lym-
phocyte transformation tests, has been frequently postu-
lated (Britschgi et al. 2001).
Figure 6 Hematoxylin and eosin staining showing the epidermis 
lined by keratinizing stratified squamous epithelium with evidence of 
spongiosis and neutrophilic infiltration (low magnification ×4).
Figure 7 Hematoxylin and eosin staining showing the epidermis 
lined by keratinizing stratified squamous epithelium with evidence of 
spongiosis. Most of the blood vessels in underlying dermis showing 
thrombus formation along with necrosis in the vascular wall and 
neutrophilic infiltration (high magnification ×10).
Figure 8 Periodic acid schiff staining of the same skin lesions show-
ing amorphus PAS positive material deposits (red arrows) in form of 
intramural and intravascular thrombus (low magnification ×4).
Figure 9 Periodic acid schiff staining of the same skin lesions show-
ing amorphus PAS positive material deposits (red arrow) in form of 
intramural and intravascular thrombus (high magnification ×20).
Page 6 of 7Bhattacharya et al. SpringerPlus  (2015) 4:302 
The prognosis for drug induced LCV is generally good, 
with most patients undergoing spontaneous resolu-
tion within weeks to months (Rojeau 2005). Therapeutic 
modalities include identification of the offending drug 
and immediate discontinuation of drugs along with sup-
portive management of the inflammatory response. 
There is increased morbidity and the potential for mor-
tality if there is involvement of other major organ systems 
like kidneys, gastrointestinal tract, lungs, heart, or central 
nervous system.
Conclusions
Nimesulide has been a contentious drug and due 
to its toxicities it has never been licensed for use in 
most developed nations of the world and has been 
withdrawn from others following reports of severe 
ADRs with this molecule. Unfortunately, the drug still 
continues to be used in many developing countries 
including India although its use in the pediatric popu-
lation has been banned in India of late (The Gazette 
of India Extraordinary 2011). Under this scenario and 
keeping in mind the reports of ADR affecting more 
than one organ system as shown in our case study, the 
scientific community should emphasize the need for 
strict pharmacovigilance with the use of molecules 
like nimesulide, especially in the developing nations 
where such monitoring systems are inadequate. Fur-
ther, as nimesulide administration is associated with 
acute liver failure, a strict enquiry about nimesulide 
intake should be made in any patient presenting with 
acute liver injury.
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